Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) presents complex genetic diversity, challenging effective treatment strategies.
• Advances in understanding CLL biology and treatment have identified novel therapeutic agents.
• Investigating signaling pathways and molecular profiling are crucial for personalized CLL therapy.

Purpose of the Study:

• To evaluate the impact of maltotriose (M3) modified fourth-generation poly(propylene imine) dendrimers (PPI-G4-M3) on NFκB pathway gene expression in CLL cells.
• To compare the effects of PPI-G4-M3 dendrimers with Fludarabine (FA) in CLL treatment models.
• To explore the potential of dendrimers as a personalized therapeutic approach for CLL.

Main Methods:

• Utilized 60K microarray analysis to assess gene expression changes in CLL (MEC-1) cells.
• Treated CLL cells with PPI-G4-M3 dendrimers and Fludarabine (FA) for comparative analysis.
• Focused on the NFκB signaling pathway, a key factor in B-cell neoplasm pathogenesis.

Main Results:

• PPI-G4-M3 dendrimers significantly modulated the expression of genes within the NFκB pathway in CLL cells.
• The observed effects of PPI-G4-M3 dendrimers on CLL cells were comparable to those of Fludarabine (FA).
• Previous studies demonstrated that PPI-G4-M3 dendrimers also affect BCR, TRAIL, and WNT signaling, inducing apoptosis and inhibiting proliferation.

Conclusions:

• PPI-G4-M3 dendrimers demonstrate significant potential in modulating gene expression relevant to CLL pathogenesis.
• These dendrimers offer a comparable therapeutic effect to Fludarabine, suggesting their viability as an alternative treatment.
• Dendrimers represent a promising class of nanomedicines for advancing personalized therapy in CLL by bridging current treatment gaps.